Suyash Prasad

Chief Medical Officer and Head of Research & Development • Taysha Gene Therapies

Dr Suyash Prasad is a Pediatrician, Clinical Development Physician, Translational Scientist and Executive Leader with 20 years in the biopharmaceutical industry. He currently serves as the Chief Medical Officer and Head of Research and Development at Taysha Gene Therapies, an organization dedicated to developing AAV gene therapy approaches for treating children and adults with severe neurological disease

Suyash graduated in medicine at the University of Newcastle upon Tyne, UK where he received commendations for Pediatrics, Obstetrics and Gynecology, and Medical Ethics. His pediatric training was completed at recognized centers of excellence in the UK and Australia before he moved to industry. His industry career progressed at Eli Lilly, Genzyme, and BioMarin, and Audentes Therapeutics (now Astellas Gene Therapies), before moving to Taysha.

He is a UK board-certified physician and is a member of the Royal College of Physicians (MRCP) and the Royal College of Paediatrics and Child Health (MRCPCH). Suyash received his Diploma in Pharmaceutical Medicine from the Royal College of Physicians of the UK, and his Masters in Translation Science with distinction from Kings College, London. He is a Fellow of the Faculty of Pharmaceutical Medicine and is a past recipient of the Outstanding Contribution award from the Faculty.

Suyash has dedicated his career to the well-being and advocacy of children who are afflicted by rare and severe disease.

Also Speaking

Nadia Lounnas-Mourey

Associate Director, Process Development • Sangamo Therapeutics

Phyllis I. Warkentin

Chief Medical Officer • Foundation for Accreditation Cellular Therapy (FACT)

Ronit Slotky

Director, Cell Therapy Manufacturing Facility • Hackensack University Medical Center

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.